Shanghai Pharmaceuticals: Ammonium glycyrrhizinate injection passes the evaluation of generic drug consistency.

Shanghai Pharmaceutical announced that recently, its subsidiary Shanghai Xinyi Jinzhu Pharmaceutical Co., Ltd. received the "Drug Supplementary Application Approval Notice" issued by the National Medical Products Administration for the injection of tranexamic acid. The drug has passed the evaluation for consistency of quality and efficacy of generic drugs. The injection of tranexamic acid is mainly used for various types of bleeding caused by acute or chronic, localized or systemic primary fibrinolysis hyperactivity. The amount of tranexamic acid injections purchased by mainland China hospitals in 2024 is 143 million RMB.